Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc. (ADXS) Revenue
Annual & quarterly revenue history · segment & region breakdown
ADXS · revenue · updated Jun 15, 2026
Core revenue metrics
Trailing 12 monthsAyala Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 94.80% year-over-year from $0.00B in FY2023.
Revenue trend
2023 – 2004 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-12-31 | $0.00B | -$0.00B | -94.80% |
| 2022-12-31 | $0.00B | -$0.00B | -92.28% |
| 2021-10-31 | $0.00B | +$0.00B | +1180.63% |
| 2020-10-31 | $0.00B | -$0.00B | -89.16% |
| 2019-10-31 | $0.00B | -$0.00B | -61.50% |
| 2018-10-31 | $0.01B | -$0.01B | -49.61% |
| 2017-10-31 | $0.01B | +$0.01B | +201.16% |
| 2016-10-31 | $0.00B | +$0.00B | — |
| 2015-10-31 | $0.00B | -$0.00B | -100.00% |
| 2014-10-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Ayala Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Ayala Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Ayala Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ADXS revenue · 4 questionsADXS's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 94.80% year-over-year from $0.00B in FY2023.
▸ Source: FMP · Ayala Pharmaceuticals, Inc. SEC filings · GAAP · Ayala Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026